Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine - Trial NCT05768126
Access comprehensive clinical trial information for NCT05768126 through Pure Global AI's free database. This Phase 4 trial is sponsored by UMC Utrecht and is currently Recruiting. The study focuses on Depressive Disorder. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
UMC Utrecht
Timeline & Enrollment
Phase 4
Sep 29, 2021
Jan 01, 2026
Primary Outcome
The effect of rivastigmine on scores of the verbal fluency test.,The effect of rivastigmine on scores of the Rey auditory verbal learning test,The effect of rivastigmine on changes in scores on the Montreal Cognitive Assessment,The effect of rivastigmine on changes in scores on the Columbia University Autobiographical Memory Interview short form,Changes in resting-state EEG peak frequency,Treatment response,Treatment response,Treatment response,Treatment response,Remission,Remission,Remission,Remission
Summary
The goal of this clinical trial is to test the beneficial effects of rivastigmine
 administration, and predict the treatment outcome with electroencephalography (EEG), in
 patients with severe depression treated with electroconvulsive therapy (ECT). The study has
 two main objectives:
 
 - to study whether rivastigmine would ameliorate the side-effect profile of ECT
 
 - to develop an outcome prediction model based on resting state EEG for both the response
 to treatment as well as its side effect
 
 Participants will be assessed by:
 
 - Cognitive tests
 
 - Questionnaires of clinical symptoms
 
 - Questionnaires of depressive symptoms
 
 - Bloodsample
 
 - Resting state and task-based EEG
 
 Researchers will compare patients with a depressive disorder treated with ECT receiving
 rivastigmine to placebo patches to see if rivastigmine reduces cognitive side effects.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05768126
Non-Device Trial